Nursing

Your Article Summary

See Latest Articles

Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09

Bansal D et al. – As there are few differences between the two treatments in efficacy, pregabalin 150 mg twice daily might be the alternative choice as it is associated with fewer adverse effects in this population.

• A randomized, double–blind, crossover, active–control, clinical trial with variable dose titration was carried out (n = 51).
• Amitriptyline orally, at doses of 10, 25 and 50 mg at night–time and pregabalin orally, at doses of 75, 150 and 300 mg twice daily, by optional titration was used.
• Each drug treatment was of 5 weeks.
• There was a placebo washout period for 3 weeks between the two drugs. Assessment for pain relief, overall improvement and adverse events were carried out.

• Good, moderate and mild pain relief were noted in 21 (48%), 6 (13%) and 7 (15%) patients on pregabalin and 15 (34%), 5 (11%) and 12 (27%) patients on amitriptyline, respectively, by patient's global assessment of efficacy and safety.
• Patient and physician's global assessment, McGill pain questionnaire, Likert pain scale and Patient Global Impression of Change showed no significant difference between the treatments, although improvement with both treatments was seen from the first week.
• Of the 52 adverse events reported, 34 (65.4%) were with amitriptyline, drowsiness being the commonest [in 19 (43%) patients]. Pregabalin caused adverse events in 18 (25%), of which drowsiness was the most common in nine (20%) patients.
• The preferred pregabalin dose was 150 mg twice daily.

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Update in treatment options for psoriatic arthritis
Expert Review of Clinical Immunology, 11/20/09

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Comparison of Simvastatin and Metformin in Treatment of Polycystic Ovary Syndrome: Prospective Randomized Trial
Journal of Clinical Endocrinology and Metabolism, 11/20/09

 See all of Clinical Pharmacology

Today in Endocrinology...keeping you current

Receive free subspecialty "5-minute updates" via email

Inflammation markers and metabolic characteristics of subjects with one-hour plasma glucose levels
Diabetes Care, 11/20/09

Indigenous Drugs in Ischemic Heart Disease in Patients with Diabetes
Journal of Alternative and Complementary Medicine, 11/20/09

Impact of Diastolic Dysfunction on the Development of Heart Failure in Diabetic Patients after Acute Myocardial Infarction
Circulation: Heart Failure, 11/20/09

 See all of Endocrinology

Today in Neurology...keeping you current

Receive free subspecialty "5-minute updates" via email

Acute back pain: benefits and risks of current treatments
Current Medical Research and Opinion, 11/20/09

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
British Journal of Cancer, 11/20/09

Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis
Diabetes Care, 11/20/09

 See all of Neurology